Horizon's Cell Lines to Aid Sanger, Mass General in Guiding Oncologics Administration with PGx

The UK-based firm will provide Sanger with more than 200 genetically defined cell lines with cancer-causing mutations, which will guide researchers working on the Genomics of Drug Sensitivity in Cancer project.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.